Related Experiment Videos
Antifungal chemotherapy: advances and perspectives
Andreas H Groll1, Thomas J Walsh
1Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. grollan@mednet.uni-muenster.de
Swiss Medical Weekly
|October 4, 2002
Summary
Advances in antifungal chemotherapy have expanded treatment options for invasive fungal infections in immunocompromised patients. New drugs and diagnostic strategies offer hope for improved prevention and management of these serious infections.
Area of Science:
- Mycology
- Infectious Diseases
- Pharmacology
Background:
- Invasive fungal infections (IFIs) are a significant cause of illness and death in immunocompromised individuals.
- The development of antifungal drugs has evolved significantly, offering new therapeutic avenues.
Purpose of the Study:
- To review the evolution of antifungal therapeutic options over the past decade.
- To discuss advances in chemoprevention, empirical therapy, and early diagnosis.
- To explore future perspectives in antifungal drug research and patient management.
Main Methods:
- Review of antifungal drug development and clinical trial methodologies.
- Analysis of progress in diagnostic and therapeutic strategies for IFIs.
- Examination of pharmacodynamic concepts in antifungal drug research.
Main Results:
- Introduction of fluconazole, itraconazole, lipid formulations of amphotericin B, echinocandins, and improved triazoles have expanded treatment choices.
- Harmonized disease definitions and standardized susceptibility testing have improved clinical trial design and interpretation.
- Advances in early diagnosis, pre-emptive therapy, and understanding of pharmacodynamics have enhanced patient care.
Conclusions:
- Despite progress, IFIs remain a critical challenge in modern medicine.
- Ongoing research in antifungal agents, diagnostics, and combination therapies holds promise for better prevention and treatment.
- Future directions include novel echinocandins, second-generation triazoles, combination therapies, and immunoreconstitution.